Market Cap 10.08M
Revenue (ttm) 1.18M
Net Income (ttm) -1.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -100.00%
Debt to Equity Ratio 0.38
Volume 8,800
Avg Vol 13,758
Day's Range N/A - N/A
Shares Out 4.35M
Stochastic %K 0%
Beta 1.37
Analysts Strong Sell
Price Target $20.33

Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 8 642 9100
Fax: 972 8 642 9101
Address:
Modi’in Technology Park, 2 HaMa’ayan Street, Hevel Modi'in, Israel
TwongStocks
TwongStocks Apr. 21 at 2:44 PM
$BLRX Their partner, Hemispheran, is publishing two GLIX1 abstracts at the 2026 ASCO Annual Meeting. GLIX1: A first-in-class oral molecule targeting the DNA damage response by restoring TET2 activity https://www.asco.org/abstracts-presentations/259219/abstract Synergistic antitumor activity of GLIX1, a small molecule TET2 activator, in combination with PARP inhibition across multiple cancers https://www.asco.org/abstracts-presentations/263530 Both abstract texts will be available on May 21 at 05:00 PM EST.
0 · Reply
JoNCherry
JoNCherry Apr. 17 at 9:57 PM
$BLRX watching closely next week
0 · Reply
JoNCherry
JoNCherry Apr. 17 at 1:57 AM
$BLRX not sure when they will release the data
1 · Reply
JoNCherry
JoNCherry Apr. 17 at 1:57 AM
0 · Reply
gargoyl
gargoyl Apr. 16 at 4:49 PM
$BLRX 👀 beastmodecoming🦍 $2.50+ !!! Watchlearn $$ 🎯 $18.99 Started position in $RUM 🍹 Adding $VSTM on dips
0 · Reply
gargoyl
gargoyl Apr. 15 at 4:40 PM
$BLRX 👀 ing 3 of 3 long the 🦋 Catalyst below , plus two additional partners: Gloria & Ayrmid licensing 🎯 $18.99 $PFE 🤔
0 · Reply
gargoyl
gargoyl Apr. 15 at 4:37 PM
$BLRX 👀 2 of 3 soon beast mode 🦍 🎯 $18.99 Long the 🦋 $REGN a partner
0 · Reply
gargoyl
gargoyl Apr. 15 at 4:35 PM
$BLRX 👀 1 of 3 Data from website Phil is hitting on all cylinders.. long the 🦋 target 🎯 $18.99 $XBI
0 · Reply
TraderJHol
TraderJHol Apr. 15 at 3:35 PM
$BLRX I wanna buy some shares but I just feel so burned by Phil. I came by to see what was popping in the chat, but I just feel so scammed. Idk if I can ever buy again.
1 · Reply
TwongStocks
TwongStocks Apr. 14 at 3:24 PM
$BLRX Update to the prospective trial testing Aphexda for MRD Sensitization in AML. Estimated study start now pushed to May 2026. https://clinicaltrials.gov/study/NCT07392970 See below. This is not testing Aphexda as an AML treatment. It is testing to see if Aphexda helps doctors measure MRD levels in AML patients after they undergo induction therapy.
1 · Reply
Latest News on BLRX
Earnings Scheduled For March 23, 2026

2026-03-23T11:11:27.000Z - 4 weeks ago

Earnings Scheduled For March 23, 2026


BioLineRx Reports 2025 Financial Results and Provides Corporate Update

Mon, 23 Mar 2026 07:00:00 -0400 - 4 weeks ago

BioLineRx Reports 2025 Financial Results and Provides Corporate Update


BioLineRx (BLRX) and Others Set to Announce Earnings

2026-03-23T00:55:17.000Z - 4 weeks ago

BioLineRx (BLRX) and Others Set to Announce Earnings


BioLineRx to Report 2025 Annual Results on March 23, 2026

Mon, 16 Mar 2026 07:00:00 -0400 - 5 weeks ago

BioLineRx to Report 2025 Annual Results on March 23, 2026


BioLineRx (BLRX) Q3 Revenue Declines Amid New Joint Venture

2025-11-24T12:34:08.000Z - 5 months ago

BioLineRx (BLRX) Q3 Revenue Declines Amid New Joint Venture


Earnings Scheduled For November 24, 2025

2025-11-24T11:11:10.000Z - 5 months ago

Earnings Scheduled For November 24, 2025


BioLine Rx's Earnings: A Preview

2025-11-21T15:01:37.000Z - 5 months ago

BioLine Rx's Earnings: A Preview


BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

Tue, 18 Nov 2025 07:00:00 -0500 - 5 months ago

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025


Earnings Scheduled For August 14, 2025

2025-08-14T08:32:32.000Z - 9 months ago

Earnings Scheduled For August 14, 2025


BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

Thu, 07 Aug 2025 07:00:00 -0400 - 9 months ago

BioLineRx to Report Second Quarter 2025 Results on August 14, 2025


Why Is Nano-Cap BioLineRx Stock Surging On Friday?

Fri, 30 May 2025 13:58:03 -0400 - 11 months ago

Why Is Nano-Cap BioLineRx Stock Surging On Friday?


Earnings Scheduled For May 27, 2025

2025-05-27T08:32:09.000Z - 11 months ago

Earnings Scheduled For May 27, 2025


A Look at BioLine Rx's Upcoming Earnings Report

2025-05-26T14:01:50.000Z - 11 months ago

A Look at BioLine Rx's Upcoming Earnings Report


BioLineRx to Report First Quarter 2025 Results on May 27, 2025

Tue, 20 May 2025 07:00:00 -0400 - 1 year ago

BioLineRx to Report First Quarter 2025 Results on May 27, 2025


BioLineRx Reports 2024 Financial Results and Provides Corporate Update

Mon, 31 Mar 2025 07:00:00 -0400 - 1 year ago

BioLineRx Reports 2024 Financial Results and Provides Corporate Update


Uncovering Potential: BioLine Rx's Earnings Preview

2025-03-28T16:01:40.000Z - 1 year ago

Uncovering Potential: BioLine Rx's Earnings Preview


BioLineRx to Report 2024 Annual Results on March 31, 2025

Mon, 24 Mar 2025 07:00:00 -0400 - 1 year ago

BioLineRx to Report 2024 Annual Results on March 31, 2025


BioLineRx Issues Letter to Shareholders

Tue, 21 Jan 2025 07:00:00 -0500 - 1 year ago

BioLineRx Issues Letter to Shareholders


Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet

2025-01-06T19:01:37.000Z - 1 year ago

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet


BioLineRx Announces $10 Million Registered Direct Offering

Mon, 06 Jan 2025 08:57:00 -0500 - 1 year ago

BioLineRx Announces $10 Million Registered Direct Offering


Earnings Scheduled For November 25, 2024

2024-11-25T08:32:08.000Z - 1 year ago

Earnings Scheduled For November 25, 2024


BioLineRx to Report First Quarter 2024 Results on May 28, 2024

May 22, 2024, 7:00 AM EDT - 2 years ago

BioLineRx to Report First Quarter 2024 Results on May 28, 2024


BioLineRx Announces $6 Million Registered Direct Offering

Apr 1, 2024, 9:00 AM EDT - 2 years ago

BioLineRx Announces $6 Million Registered Direct Offering


TwongStocks
TwongStocks Apr. 21 at 2:44 PM
$BLRX Their partner, Hemispheran, is publishing two GLIX1 abstracts at the 2026 ASCO Annual Meeting. GLIX1: A first-in-class oral molecule targeting the DNA damage response by restoring TET2 activity https://www.asco.org/abstracts-presentations/259219/abstract Synergistic antitumor activity of GLIX1, a small molecule TET2 activator, in combination with PARP inhibition across multiple cancers https://www.asco.org/abstracts-presentations/263530 Both abstract texts will be available on May 21 at 05:00 PM EST.
0 · Reply
JoNCherry
JoNCherry Apr. 17 at 9:57 PM
$BLRX watching closely next week
0 · Reply
JoNCherry
JoNCherry Apr. 17 at 1:57 AM
$BLRX not sure when they will release the data
1 · Reply
JoNCherry
JoNCherry Apr. 17 at 1:57 AM
0 · Reply
gargoyl
gargoyl Apr. 16 at 4:49 PM
$BLRX 👀 beastmodecoming🦍 $2.50+ !!! Watchlearn $$ 🎯 $18.99 Started position in $RUM 🍹 Adding $VSTM on dips
0 · Reply
gargoyl
gargoyl Apr. 15 at 4:40 PM
$BLRX 👀 ing 3 of 3 long the 🦋 Catalyst below , plus two additional partners: Gloria & Ayrmid licensing 🎯 $18.99 $PFE 🤔
0 · Reply
gargoyl
gargoyl Apr. 15 at 4:37 PM
$BLRX 👀 2 of 3 soon beast mode 🦍 🎯 $18.99 Long the 🦋 $REGN a partner
0 · Reply
gargoyl
gargoyl Apr. 15 at 4:35 PM
$BLRX 👀 1 of 3 Data from website Phil is hitting on all cylinders.. long the 🦋 target 🎯 $18.99 $XBI
0 · Reply
TraderJHol
TraderJHol Apr. 15 at 3:35 PM
$BLRX I wanna buy some shares but I just feel so burned by Phil. I came by to see what was popping in the chat, but I just feel so scammed. Idk if I can ever buy again.
1 · Reply
TwongStocks
TwongStocks Apr. 14 at 3:24 PM
$BLRX Update to the prospective trial testing Aphexda for MRD Sensitization in AML. Estimated study start now pushed to May 2026. https://clinicaltrials.gov/study/NCT07392970 See below. This is not testing Aphexda as an AML treatment. It is testing to see if Aphexda helps doctors measure MRD levels in AML patients after they undergo induction therapy.
1 · Reply
focafoca99
focafoca99 Apr. 8 at 7:54 PM
$BLRX partner Hemispherian started a Phase 1/2a trial of GLIX1 in glioblastoma.
0 · Reply
tankwfwf
tankwfwf Apr. 5 at 12:37 AM
$BLRX always remember that Phil took this stock and did everything he could to fuck it up, offering at 80 cents when the share price was 1.20. 40 to 1 stock split after holly and her band of merry fuck-ups blew 6 million a quarter to make a million. And Phil is still spouting the magic zizzwheel that the company can't afford without another bullshit offering. Remember this guy lied to the stockholders and the SEC COULD CARE LESS. I hope he gets the reward he deserves.
1 · Reply
DiaJay
DiaJay Apr. 2 at 7:17 PM
$BLRX Perpetual Disappointmen.
0 · Reply
gargoyl
gargoyl Apr. 1 at 3:12 PM
$BLRX 👀 about to explode MM book split open , can’t dark pool this story anymore, watch and learn Beast 🦍 mode inevitable Long the 🦋 🎯 $18.99
0 · Reply
gargoyl
gargoyl Apr. 1 at 3:07 PM
$BLRX 👀 BiolineRx playing with big boyz … 🎯 $18.99 $MRK $AZN
0 · Reply
gargoyl
gargoyl Apr. 1 at 3:01 PM
$BLRX 👀 Value and Growth Target 🎯 $18.99 $XBI $REGN $PFE
0 · Reply
TwongStocks
TwongStocks Mar. 27 at 8:15 PM
$BLRX As mentioned a month ago, the SEC is finally requiring insiders at foreign issuers like BLRX to report insider transactions. Phil Serlin's Form 3 was filed today, which reports his current shares and options. When he makes trades, he will make Form 4 filings. https://www.sec.gov/Archives/edgar/data/1493277/000117891326001790/xslF345X06/zk2634968.xml The Form 3 reports the number of ordinary shares. For those who trade the ADS on NASDAQ, 1 ADS = 600 ordinary shares. Phil owns: • 5,131,800 ordinary shares (equivalent to 8,553 ADS) • 14,218,800 options at prices ranging from $0.045 to $0.287. In terms of ADS, that's the equivalent of 23,698 options at prices ranging from $27 to $172.20.
0 · Reply
tankwfwf
tankwfwf Mar. 26 at 10:04 PM
$BLRX probably about the time Phil makes an offering that will fuck the shares that are ADR's. Just watch the way he does an ER and then a few days latter announces something that he could have announced at the ER. He is just polishing a turd..
0 · Reply
Biotechs5454
Biotechs5454 Mar. 26 at 2:02 PM
$BLRX Anyone know offhand when the next ADR fee will be charged? TIA
0 · Reply
ABDeb
ABDeb Mar. 26 at 1:54 PM
0 · Reply
TwongStocks
TwongStocks Mar. 26 at 11:18 AM
$BLRX BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) https://www.prnewswire.com/news-releases/biolinerx-announces-initiation-of-phase-12a-study-of-glix1-for-the-treatment-of-glioblastoma-gbm-302725980.html The Phase 1 part of the trial is expected to recruit up to 30 patients with recurrent and progressive GBM and other high-grade glioma. The objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy. Data from the Phase 1 part of the trial are anticipated in H1 2027.
0 · Reply
DARKP00L
DARKP00L Mar. 26 at 11:17 AM
$BLRX 07:17 on Mar. 26 2026 BioLineRx Launches First Human Trial For Brain Cancer Drug #tradeideas
0 · Reply